Evans Terry L 4

What Happened
Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals, reported an exercise/conversion transaction (code M) on 2026-04-30 in which 168 shares were acquired at $0. The filing shows these shares were released from restrictions tied to a prior award; no cash was paid in this transaction.

Key Details

• Transaction date and price: 2026-04-30, 168 shares @ $0.00 (reported as Acquired; code M).
• Filing date: 2026-05-01 (filed the next day).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: F1 — "Represents shares released from restriction from shares awarded 3/28/2025."
• No sale or cashless disposition reported here; this is a release/vesting event, not a market sale.

Context
This was a release/vesting of previously awarded shares (converted/exercised) rather than an open‑market purchase or sale. Because the shares were acquired at $0 as part of an award, the transaction doesn't by itself signal a purchase-driven bullish bet; subsequent sales or purchases would be reported separately.